Maze

Bantam Tools New ArtFrame Art System Brings AI Art to Life at Whitney Museum of American Art Harold Cohen Exhibition - February 3 through May 2024

Retrieved on: 
Thursday, January 25, 2024

NEW YORK, Jan. 25, 2024 /PRNewswire-PRWeb/ -- The new exhibit Harold Cohen: AARON, opening at the Whitney Museum of American Art on February 3, 2024, examines the historical foundations of AI artmaking and provides a deep exploration of creativity, authorship, and collaboration in the context of AI. The machines making the AI-generated art for the exhibit are the Bantam Tools ArtFrame system, a new product created for the Whitney exhibit by Bantam Tools. The Bantam Tools ArtFrame is an extensible art machine system with modular tool heads for artists to create physical art from digital designs with traditional materials. The exhibit is open to the public February 3 through May 2024 and more information is available at whitney.org.

Key Points: 
  • The machines making the AI-generated art for the exhibit are the Bantam Tools ArtFrame system, a new product created for the Whitney exhibit by Bantam Tools.
  • The ArtFrame Art Machine System that is part of the Harold Cohen: AARON exhibit at the Whitney Museum of American Art, is just one of the new machines that Bantam Tools is launching in 2024.
  • To learn more about the Bantam Tools ArtFrame Art System and Bantam Tools NextDraw, drawing machine, visit bantamtools.com .
  • Harold Cohen: AARON is organized by Christiane Paul, curator of Digital Art, with David Lisbon, curatorial assistant of the Whitney Museum of American Art, with ArtFrame plotters provided by Bantam Tools.

Statement Regarding the Termination of Sanofi’s Proposed Acquisition of Maze Therapeutics’ Pompe Disease Drug

Retrieved on: 
Wednesday, January 3, 2024

Following Sanofi’s decision to terminate its proposed acquisition of an exclusive license to Maze Therapeutics Inc.’s developmental drug to treat Pompe disease, the Federal Trade Commission moved to dismiss its case challenging the transaction.

Key Points: 
  • Following Sanofi’s decision to terminate its proposed acquisition of an exclusive license to Maze Therapeutics Inc.’s developmental drug to treat Pompe disease, the Federal Trade Commission moved to dismiss its case challenging the transaction.
  • The proposed deal would have allowed Sanofi to maintain its monopoly power by eliminating nascent competition, in turn reducing innovation for lifesaving, essential care.
  • The deal also would have enabled Sanofi to continue charging patients monopoly prices of over $750,000 for an annual course of treatment for its Pompe therapies.
  • For the latest news and resources, follow the FTC on social media, subscribe to press releases and read our blog.

Press Release: Statement on FTC challenge to proposed license agreement with Maze Therapeutics

Retrieved on: 
Monday, December 11, 2023

Sanofi is disappointed with the Federal Trade Commission’s announcement that it is seeking a preliminary injunction against a proposed licensing agreement between Sanofi and Maze Therapeutics.

Key Points: 
  • Sanofi is disappointed with the Federal Trade Commission’s announcement that it is seeking a preliminary injunction against a proposed licensing agreement between Sanofi and Maze Therapeutics.
  • We respectfully disagree with the action by the FTC which also delays potential advancements that could impact the lives of patients.
  • The Maze partnership was designed to apply Sanofi’s resources, knowledge, and expertise to accelerate the development of MZE001, with the hope of addressing unmet medical needs for this devastating condition.
  • Sanofi remains committed to address the Pompe patient community’s unmet needs.

Maze Therapeutics Announces Initiation of Dosing in Phase 1 Trial Evaluating MZE829, a Novel Oral APOL1 Inhibitor, as a Potential Treatment for APOL1 Kidney Disease

Retrieved on: 
Thursday, December 14, 2023

Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced the initiation of dosing in the company’s Phase 1 trial of MZE829 in healthy volunteers.

Key Points: 
  • Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced the initiation of dosing in the company’s Phase 1 trial of MZE829 in healthy volunteers.
  • MZE829 is an oral, small molecule apolipoprotein L1 (APOL1) inhibitor designed to block APOL1 pore function and ameliorate manifestations of APOL1 kidney disease.
  • Genetic variants of the gene (G1 and G2) are associated with increased risk for a spectrum of progressive kidney diseases in the Black community.
  • Maze anticipates reporting data from the trial in the second half of 2024 to support advancement into the Phase 2 clinical program in patients.

Shattering Its Previous Records by a Significant Margin... Riyadh International Philosophy Conference 2023 Concludes Its Activities for This Year

Retrieved on: 
Monday, December 11, 2023

The Commission announced the conference's remarkable outcomes and strategic accomplishments over its three days, including partnerships with 12 local and international partners, the public signing of the Saudi Philosophy Society's membership into the International Union of Philosophical Societies, and its addition to the International Philosophy Conference (Rome, 2024).

Key Points: 
  • The Commission announced the conference's remarkable outcomes and strategic accomplishments over its three days, including partnerships with 12 local and international partners, the public signing of the Saudi Philosophy Society's membership into the International Union of Philosophical Societies, and its addition to the International Philosophy Conference (Rome, 2024).
  • In this context, the Commission expressed the conference's significant focus on research advancement and academic growth, having received 144 scientific proposals from more than 20 countries.
  • These proposals were peer-reviewed and evaluated by the Saudi Journal of Philosophical Studies, with approximately 39 proposals selected for discussion at the conference venues.
  • During its three days, the conference presented a variety of interactive experiences that visitors praised for their diversity, aimed at simplifying philosophical concepts for attendees.

Shattering Its Previous Records by a Significant Margin... Riyadh International Philosophy Conference 2023 Concludes Its Activities for This Year

Retrieved on: 
Monday, December 11, 2023

The Commission announced the conference's remarkable outcomes and strategic accomplishments over its three days, including partnerships with 12 local and international partners, the public signing of the Saudi Philosophy Society's membership into the International Union of Philosophical Societies, and its addition to the International Philosophy Conference (Rome, 2024).

Key Points: 
  • The Commission announced the conference's remarkable outcomes and strategic accomplishments over its three days, including partnerships with 12 local and international partners, the public signing of the Saudi Philosophy Society's membership into the International Union of Philosophical Societies, and its addition to the International Philosophy Conference (Rome, 2024).
  • In this context, the Commission expressed the conference's significant focus on research advancement and academic growth, having received 144 scientific proposals from more than 20 countries.
  • These proposals were peer-reviewed and evaluated by the Saudi Journal of Philosophical Studies, with approximately 39 proposals selected for discussion at the conference venues.
  • During its three days, the conference presented a variety of interactive experiences that visitors praised for their diversity, aimed at simplifying philosophical concepts for attendees.

Maze Therapeutics Highlights New Preclinical Data Supporting Advancement of APOL1 Inhibitor Candidate Toward Clinical Evaluation for APOL1 Kidney Disease

Retrieved on: 
Saturday, November 4, 2023

Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced findings from preclinical studies demonstrating the potential of a novel APOL1 inhibitor to reverse disease manifestations of APOL1 kidney disease in a chronic APOL1 kidney disease mouse model.

Key Points: 
  • Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced findings from preclinical studies demonstrating the potential of a novel APOL1 inhibitor to reverse disease manifestations of APOL1 kidney disease in a chronic APOL1 kidney disease mouse model.
  • The data are being presented today during a poster session at the American Society of Nephrology Kidney Week 2023 in Philadelphia.
  • “Leveraging our Maze Compass™ platform, our scientists have been able to uncover a more robust understanding of APOL1 kidney disease that gives us confidence in our approach to inhibiting APOL1 with an oral, small molecule.
  • Based on these findings, Maze plans to evaluate development candidate MZE829 as a treatment for APOL1 kidney disease with a Phase 1 healthy volunteer trial expected to begin by the end of 2023.

New Children's Book, 'Poopie Creates a Habit: Life Skills for All Ages,' Is Now Available for Purchase in Bookstores and on Amazon

Retrieved on: 
Thursday, October 12, 2023

The newest release from Poopie The Cat called 'Poopie Creates a Habit: Life Skills for All Ages,' takes young readers on an exciting adventure by teaching important life lessons.

Key Points: 
  • This compelling new book, published in large print in 2023, is now available for purchase at bookstores and online on Amazon.
  • This 36-page masterwork is expertly crafted to appeal to children of all ages, with vivid graphics expertly interwoven into a captivating plot.
  • Poopie Creates a Habit plants the seeds for foundational life skills that will blossom as the child adventures into adulthood.
  • Visit Poopie's website and Poopie's Instagram to learn more about "Poopie Creates a Habit: Life Skills for All Ages," request an interview with the author, and more.

The Maze Group announces Nick Thomson as Head of Partnerships

Retrieved on: 
Monday, October 16, 2023

The Maze Group announces that Nick Thomson has joined as Head of Partnerships, reporting to Vince Santo, CEO.

Key Points: 
  • The Maze Group announces that Nick Thomson has joined as Head of Partnerships, reporting to Vince Santo, CEO.
  • Nick joins from The Stable (part of Accenture Song) where he was VP Partnerships for their Direct-to-Consumer division.
  • “I am tremendously excited to bring my Shopify Enterprise experience to The Maze Group.
  • The Maze Group’s extensive Enterprise experience and strong team are stand out factors in why I joined,” said Nick.

Maze Therapeutics to Present New Data for APOL1 Kidney Disease in Proprietary Chronic Preclinical Model Demonstrating Reversal of Albuminuria

Retrieved on: 
Friday, October 13, 2023

Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that the company will present new preclinical data highlighting the potential of its small molecule APOL1 inhibitor as a treatment for APOL1 kidney disease.

Key Points: 
  • Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that the company will present new preclinical data highlighting the potential of its small molecule APOL1 inhibitor as a treatment for APOL1 kidney disease.
  • The data will be presented during a poster session at the American Society of Nephrology’s Kidney Week 2023, from November 2-5, 2023, in Philadelphia.
  • “Our latest findings that we will present at ASN are further demonstration of our program’s potential to treat a significant sub-population suffering from chronic kidney disease.
  • It also underscores the power of the Maze Compass platform to elucidate important insights into the genetic drivers of disease.”